## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($52.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Is CRISPR Therapeutics (CRSP) Attractively Priced After Recent Gene Editing Progress?**
- Source: Simply Wall Street | 20260107T164107 | Bullish | Relevance: 100%
- CRISPR Therapeutics (CRSP) is currently being evaluated for its attractiveness as an investment following recent share movements and gene editing progress. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 69.9% at US$58.19, with an estimated intrinsic value of US$193.06 per share. However, a Price-to-Book (P/B) ratio analysis indicates the stock is "about right" in its pricing compared to the broader Biotech industry.

**2. CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: GlobeNewswire | 20260105T083000 | Bullish | Relevance: 100%
- CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT in San Francisco. A live webcast and subsequent replay will be available on the company's investor relations website. CRISPR Therapeutics is a gene editing company developing transformative medicines, known for CASGEVYÂ®, the world's first CRISPR-based therapy.

**3. Assessing CRISPR Therapeutics (CRSP) Valuation As Investor Interest Returns**
- Source: Simply Wall Street | 20260105T080935 | Somewhat-Bullish | Relevance: 100%
- CRISPR Therapeutics (CRSP) has re-entered investor focus with a current share price of US$53.77 and mixed recent returns, suggesting renewed interest. The company's valuation is explored through its price-to-book ratio and a discounted cash flow model, indicating it might be undervalued compared to peers and its intrinsic worth despite ongoing losses. Investors are encouraged to consider the potential upsides alongside the risks associated with its pipeline programs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Needham | $80 | $80 | 0% |
| 2025-12-23 | Citizens | $86 | $86 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Needham | reit | Buy |
| 2025-12-23 | Citizens | reit | Market Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($4.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $4.0M in recent transactions.
2. High short interest (25.8%, 10.4 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +8.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1964% YoY. Insider selling cluster ($4.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.5B |
| Beta | 1.70 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 25.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -5.9% to 2.8% (+8.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.2pp (needs >4.0% for momentum thesis). MRS_5 at 3.7% confirms short-term momentum alignment. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.78% (CS: 76) | Neutral |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $57.99
- **Stop Loss:** $52.45 (9.6% risk)
- **Target:** $63.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 216
- **Position Value:** $12,525.84
- **Portfolio %:** 12.53%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*